Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study

Daniel Tuyet Kristensen*, Lars Børty Nielsen, Lasse Hjort Kyneb Jakobsen, Tove Christina Choe Kristensen, Lene Østergaard Jepsen, Claudia Schöllkopf, Kim Theilgaard-Mönch, Tarec Christoffer El-Galaly, Anne Stidsholt Roug, Marianne Tang Severinsen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

51 Downloads (Pure)


Overweight patients with cancer are frequently reduced in chemotherapy dose due to toxicity concerns, although previous studies have indicated that dose reduction (DR) of overweight patients results in comparable toxicity but may compromise overall survival (OS). Current evidence regarding DR in patients with acute myeloid leukaemia (AML) is limited. To investigate the association between DR and outcome among overweight patients with AML we analysed a Danish nationwide cohort of overweight adult AML patients treated with remission induction chemotherapy. Among 536 patients identified, 10.1% were categorized as DR defined as 95% or less of full body surface area (BSA)-based dose. Risk factors for DR were high body mass index (BMI) and BSA, therapy-related AML and favourable cytogenetics. No significant differences were observed for rates of complete remission (CR), 30- and 90-day mortality between DR and non-DR patients. Furthermore, DR did not affect median relapse-free survival (RFS) [DR, 14.5 (95% confidence interval, 9.0–41.7) months; non-DR, 15.0 (12.3–19.3)] with an adjusted difference in five-year restricted mean survival time (Δ5y-RMST) of 0.2 (−8.4 to 8.8) months nor median OS (DR, 17.0 [11.9 to 45.5] months; non-DR, 17.5 [14.8 to 20.5]) with an adjusted Δ5y-RMST of 0.8 (−5.7 to 7.3) months. In conclusion, we found no statistically significant association between DR and outcomes among overweight patients with AML. However, we acknowledge the limited sample size and encourage further studies in this important subject.

Original languageEnglish
JournalBritish Journal of Haematology
Issue number4
Pages (from-to)539-548
Publication statusPublished - Nov 2022

Bibliographical note

Publisher Copyright:
© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.


  • acute leukaemia
  • chemotherapy
  • dose reduction
  • overweight and obesity
  • survival


Dive into the research topics of 'Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study'. Together they form a unique fingerprint.

Cite this